Generex Biotechnology Corp. (GNBT) spins out, stock points higher

Posted on: September 15th, 2011
Written by:

Generex Biotechnology Corp. (OTCBB: GNBT) saw its shares gain 8.7% to 9.89 cents, as Thursday’s markets closed, on news of the spinout of one of its subsidiaries. Volume for the stock was 1.3 million shares, nosing out its full-day average.

A news release dated Sept. 15 announced that the company, based in Worcester, Mass., provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc.

The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.

Generex CEO Mark Fletcher, “We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout.

“We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an initial fund raising. If the merger and the initial fund raising are successful, we will then seek a listing of the merged company’s stock on a national stock exchange.”

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.

no comments

Generex Biotechnology Corporation (GNBT) advances on product speculation

Posted on: June 16th, 2011
Written by:

Generex Biotechnology Corporation (OTCBB: GNBT) shares leaped 8.3% Thursday to 20 cents, amid word of progress on the company’s new product. Volume for the stock totaled nearly 797,000 shares, a mite short of its daily average of 878,500 as the closing bell neared.

In a news release dated June 16, Generex issued a synopsis of the update on the clinical and regulatory program for Generex Oral-lyn(TM), the Company’s proprietary buccal insulin spray product, provided at the annual meeting of the Company’s stockholders held in New York City on June 8.

At that meeting, the current status, clinical study plans, and major market registration pathway for Generex Oral-lyn(TM) were presented. Dr. James H. Anderson, Jr., MD, FFPM, FACE, Generex’s Senior Scientific Advisor, outlined the reorganization within the Company’s medical/regulatory group.

Generex received written guidance from the U.S. Food and Drug Administration (FDA) in late May in response to data submitted on Generex Oral-lyn(TM). There were no safety issues identified in the clinical trials, nor safety questions raised by the FDA.

As resources and opportunities allow, Generex will seek to maximize the benefits and value of the Generex RapidMist(TM) drug delivery system for delivering new drugs, new proteins, and new enzymes for improved treatment of diabetes and other diseases.

No officials from Generex were available for comment.

Based out of Worcester, Mass., Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.

no comments

About Penny Stocks

The term "penny stocks," also known as micro-cap equities, micro caps, small caps, pink sheets, refers to shares in a company that trades for less than $5.00. Most penny stocks trade on the OTCBB market and the pink sheet electronic quotation service. Penny Stocks can be very volatile and can see gains as much as 500% in a day. Volatility in penny stocks is also dangerous because penny stocks can come down as quickly as they go up. If you trade penny stocks based on stock picks, make sure to always do your due diligence on the companies you're considering, use stop loss orders, and book your profits when you are in a position to do so.